Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone metastasis or multiple myeloma: A 12-year longitudinal nationwide healthcare database study

被引:36
作者
Baek, Yeon-Hee [1 ]
Jeon, Ha-Lim [1 ]
Oh, In-Sun [1 ]
Yang, Hyowon [2 ]
Park, Jeehye [2 ]
Shin, Ju-Young [1 ]
机构
[1] Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea
[2] Amgen Korea Ltd, Seoul, South Korea
关键词
Skeletal-related events (SREs); Bone metastasis; Breast cancer; Prostate cancer; Multiple myeloma; US MEDICARE BENEFICIARIES; POPULATION-BASED ANALYSIS; ZOLEDRONIC ACID; SOLID TUMORS; DISEASE; MEN; COMPLICATIONS; MECHANISMS; DENOSUMAB; SURVIVAL;
D O I
10.1016/j.canep.2019.05.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: This study examined the incidence of skeletal-related events (SRE) among patients with breast cancer (BC)- or prostate cancer (PC)-induced bone metastasis or multiple myeloma (MM) based on a populationbased, 12-year healthcare database. Methods: Patients aged >= 18 years with bone metastasis from BC or PC or with MM between 2004 and 2015 were included. SRE was defined as pathologic fracture, spinal cord compression, radiation, or surgery to bone. Patients were followed-up from the initial diagnosis of bone metastasis (for those with BC or PC) or MM until SRE occurrence. To estimate multiple SREs, we applied a 21-day time window to ensure that subsequent SREs occurred independently from the previous event. We calculated the incidence and 95% confidence intervals (CIs), stratified according to the previous SRE history. Results: Our cohort included 53,231 patients, including 23,811 with BC, 19,170 with PC, and 10,250 with MM. The incidence of multiple SREs in the 21-day time window was 1.03 (95% CI = 1.01-1.05) in patients with previous SRE history and 0.19 (95% CI = 0.19-0.20) in those without. The cumulative SRE incidences were 47%, 31.4%, and 38.0% in BC, PC, and MM patients. Conclusion: The incidences of multiple SREs in BC- or PC-induced bone metastasis or MM in this 12-year South Korean cohort were slightly higher than those in European countries. Our study provided real-world evidence that patients with BC- or PC-induced bone metastasis or MM are at high risk of SRE.
引用
收藏
页码:104 / 110
页数:7
相关论文
共 38 条
  • [1] [Anonymous], 2008, Modern epidemiology
  • [2] [Anonymous], 2013, CLIN GUID PREV TREAT
  • [3] Brown J. E., 2019, BREAST CANC RES TREA, V123, P767
  • [4] Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art
    Clemons, M.
    Gelmon, K. A.
    Pritchard, K. I.
    Paterson, A. H. G.
    [J]. CURRENT ONCOLOGY, 2012, 19 (05) : 259 - 268
  • [5] Metastatic bone disease: clinical features, pathophysiology and treatment strategies
    Coleman, RE
    [J]. CANCER TREATMENT REVIEWS, 2001, 27 (03) : 165 - 176
  • [6] INCREASE IN SERUM BONE GAMMA-CARBOXYGLUTAMIC ACID PROTEIN WITH AGING IN WOMEN - IMPLICATIONS FOR THE MECHANISM OF AGE-RELATED BONE LOSS
    DELMAS, PD
    STENNER, D
    WAHNER, HW
    MANN, KG
    RIGGS, BL
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1983, 71 (05) : 1316 - 1321
  • [7] Comparison of whole-body MR imaging and conventional X-ray examination in patients with multiple myeloma and implications for therapy
    Dinter, Dietmar Joerg
    Neff, Wolfgang K.
    Klaus, Johanna
    Boehm, Christoph
    Hastka, Jan
    Weiss, Christel
    Schoenberg, Stefan O.
    Metzgeroth, Georgia
    [J]. ANNALS OF HEMATOLOGY, 2009, 88 (05) : 457 - 464
  • [8] Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
    Fizazi, Karim
    Carducci, Michael
    Smith, Matthew
    Damiao, Ronaldo
    Brown, Janet
    Karsh, Lawrence
    Milecki, Piotr
    Shore, Neal
    Rader, Michael
    Wang, Huei
    Jiang, Qi
    Tadros, Sylvia
    Dansey, Roger
    Goessl, Carsten
    [J]. LANCET, 2011, 377 (9768) : 813 - 822
  • [9] Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates
    Fizazi, Karim
    Lipton, Allan
    Mariette, Xavier
    Body, Jean-Jacques
    Rahim, Yasmin
    Gralow, Julie R.
    Gao, Guozhi
    Wu, Ling
    Sohn, Winnie
    Jun, Susie
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (10) : 1564 - 1571
  • [10] OSTEOPOROSIS IN HYPOGONADAL MEN - ROLE OF DECREASED PLASMA 1,25-DIHYDROXYVITAMIN-D, CALCIUM MALABSORPTION, AND LOW BONE-FORMATION
    FRANCIS, RM
    PEACOCK, M
    AARON, JE
    SELBY, PL
    TAYLOR, GA
    THOMPSON, J
    MARSHALL, DH
    HORSMAN, A
    [J]. BONE, 1986, 7 (04) : 261 - 268